Feb 4, 2021 · Herein, we present 4 illustrative cases of NPM1 -mutated AML that address important issues surrounding the biology, diagnosis, and therapy of this common form of leukemia.

Oct 8, 2020 · NPM1 mutations represent the most common genetic lesion in adult acute myeloid leukemia (AML; about one third of cases), and they act deterministically to cause the aberrant cytoplasmic delocalization of NPM1 mutants.

Jun 20, 2022 · AML, NOS is subclassified based on morphological and cytochemical/immunophenotypic features of leukemic cells, indicating the lineages involved and their degree of maturation.

NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. NPM1-mutated AML is recognizable by molecular techniques and immunohistochemistry, which, when combined, can solve difficult diagnostic problems ...

Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1 -mutated AML has been recognized as distinct entity in the 2017 World Health Organization (WHO) classification of lympho-haematopoietic neoplasms.

NPM1 mutations are the most common genetic alteration in acute myeloid leukemia (AML), detected in about 30–35% of adult AML and more than 50% of AML with normal karyotype.

Our findings provide additional evidence of association between NPM1-mutated AML with TET2 or IDH2 co-mutations and the APL-like immunophenotype. This AML subset was found to exist in both de novo and secondary AML.

Feb 4, 2021 · Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1-mutated AML exhibits unique molecular, pathological, and clinical features, which led to its recognition as distinct entity in th …

Nov 20, 2022 · Nucleophosmin 1 (NPM1) is the most common genetic alteration in acute myeloid leukemia (AML), detected in 30-35 percent of adult AML and more than 50 percent of AML with normal karyotype. It also has “peculiar molecular and clinicopathological features,” report the authors of a new research paper published in Leukemia .

May 9, 2024 · In this issue of Blood, Othman et al have identified the level of molecular measurable residual disease (MRD) in peripheral blood after 2 cycles of intensive chemotherapy that could guide the indication for transplantation in patients with acute myeloid leukemia (AML) with NPM1 mutation. 1